secwatch.observer — SEC 8-K summary
======================================

Issuer:     RxSight, Inc. (RXST)
CIK:        0001111485
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-010478
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RxSight preliminary Q4 2025 revenue ~$32.6M, FY2025 revenue ~$134.5M above guidance; appoints Mark Wilterding CFO
--------------------------------------------------------------------------------

- Q4 2025 revenue ~$32.6M; FY2025 revenue ~$134.5M vs prior guidance $125-130M.
- LAL procedure volume 28,611 in Q4 (+10% QoQ) and 109,615 in FY2025 (+12% YoY).
- Installed LDD base reached 1,134 as of Dec 31, 2025 (25 LDDs sold in Q4).
- Cash & short-term investments ~$228.1M as of Dec 31, 2025.
- Mark Wilterding appointed CFO effective Jan 11, 2026, replacing Shelley Thunen (consulting role).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1111485/000119312526010478/0001193125-26-010478-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1111485/000119312526010478/rxst-20260111.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-010478

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer